PTC Therapeutics, Inc. $PTCT Shares Sold by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. lowered its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 15.4% in the 3rd quarter, Holdings Channel reports. The fund owned 91,136 shares of the biopharmaceutical company’s stock after selling 16,620 shares during the period. Hillsdale Investment Management Inc.’s holdings in PTC Therapeutics were worth $5,593,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of PTCT. Hood River Capital Management LLC grew its position in PTC Therapeutics by 654.4% in the 2nd quarter. Hood River Capital Management LLC now owns 636,502 shares of the biopharmaceutical company’s stock worth $31,087,000 after purchasing an additional 552,130 shares during the last quarter. State Street Corp grew its holdings in PTC Therapeutics by 22.1% in the 2nd quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock worth $146,347,000 after buying an additional 541,558 shares in the last quarter. Man Group plc increased its position in PTC Therapeutics by 157.4% in the 2nd quarter. Man Group plc now owns 671,513 shares of the biopharmaceutical company’s stock valued at $32,797,000 after acquiring an additional 410,653 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in PTC Therapeutics in the 2nd quarter valued at approximately $10,153,000. Finally, Squarepoint Ops LLC raised its stake in PTC Therapeutics by 1,603.8% during the 2nd quarter. Squarepoint Ops LLC now owns 181,978 shares of the biopharmaceutical company’s stock valued at $8,888,000 after acquiring an additional 171,297 shares in the last quarter.

PTC Therapeutics Price Performance

Shares of PTCT opened at $70.66 on Friday. The firm’s 50 day moving average is $74.91 and its 200-day moving average is $68.02. PTC Therapeutics, Inc. has a 12-month low of $35.95 and a 12-month high of $87.50. The stock has a market capitalization of $5.67 billion, a P/E ratio of 9.13 and a beta of 0.48.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The business had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. PTC Therapeutics had a net margin of 39.44% and a negative return on equity of 373.67%. The firm’s revenue for the quarter was down 22.7% on a year-over-year basis. During the same period in the prior year, the company earned ($0.85) earnings per share. As a group, equities research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Analysts Set New Price Targets

PTCT has been the subject of several recent analyst reports. TD Cowen reissued a “hold” rating on shares of PTC Therapeutics in a research note on Thursday, January 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of PTC Therapeutics in a report on Friday. The Goldman Sachs Group boosted their price target on shares of PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a research report on Wednesday, November 5th. Jefferies Financial Group upped their price target on shares of PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Finally, Bank of America lowered their price objective on shares of PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating on the stock in a research note on Friday. Ten investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, PTC Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $80.73.

Insider Buying and Selling at PTC Therapeutics

In related news, CAO Christine Marie Utter sold 2,494 shares of PTC Therapeutics stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $172,983.84. Following the transaction, the chief accounting officer directly owned 70,199 shares in the company, valued at $4,869,002.64. The trade was a 3.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Pierre Gravier sold 2,992 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $207,525.12. Following the sale, the chief financial officer directly owned 87,318 shares in the company, valued at $6,056,376.48. This trade represents a 3.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 298,246 shares of company stock worth $23,393,870. 5.50% of the stock is owned by insiders.

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.